Processa Pharmaceuticals, Inc. Stock Analysis & AI Score
Processa Pharmaceuticals, Inc. (PCSA) has an ST Score of 46.8 (C+), driven by its Forecast (A) and held back by its Momentum (C-). Analysts rate it Buy with a $225.00 price target (+12611.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AIPCSA Stock Price History
PCSA Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
PCSA Latest Stock News
ST Score
Processa Pharmaceuticals, Inc. (PCSA) has an ST Score of 46.8 (C+), driven by its Forecast (A) and held back by its Momentum (C-). Analysts rate it Buy with a $225.00 price target (+12611.9% upside).
- Strongest
- ForecastA
- Weakest
- MomentumC-
All factor grades
- ForecastA
- GrowthA-
- ValuationB-
- ProfitabilityC-
- Financial StrengthC-
- MomentumC-
- Piotroski1/9
Press Releases
Company Contact Details
PCSA stock: frequently asked questions
What is PCSA's ST Score?
Processa Pharmaceuticals, Inc. (PCSA) has an ST Score of 46.8 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PCSA a buy, hold, or sell?
Analysts rate PCSA a Buy, with a price target of $225.00 (+12611.9% vs the current price). Our ST Score grades it C+ (46.8/100). The ST Score is a data-driven signal, not a recommendation.
What are PCSA's factor grades?
Valuation B-, Profitability C-, Financial Strength C-, Momentum C-, Growth A-, Forecast A.
What is PCSA's valuation grade?
Processa Pharmaceuticals, Inc. (PCSA) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PCSA's growth grade?
Processa Pharmaceuticals, Inc. (PCSA) earns a growth grade of A-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PCSA's profitability grade?
Processa Pharmaceuticals, Inc. (PCSA) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PCSA's financial strength grade?
Processa Pharmaceuticals, Inc. (PCSA) earns a financial strength grade of C-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PCSA?
The average analyst price target for Processa Pharmaceuticals, Inc. (PCSA) is $225.00 from 5 analysts, which is +12611.9% versus the recent price of $1.77.
What is PCSA's Piotroski score?
Processa Pharmaceuticals, Inc. (PCSA) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.